This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.
Can Intercept (ICPT) Beat Estimates this Earnings Season?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.
Will Radius Health (RDUS) Disappoint this Earnings Season?
by Zacks Equity Research
Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.
Gigamon (GIMO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect fiscal second-quarter earnings of Gigamon (GIMO) to gain traction from product launches.
DST Systems (DST) Q2 Earnings: Is a Surprise in Store?
by Zacks Equity Research
DST Systems' (DST) continued share buybacks and dividend payments are likely to remain tailwinds in Q2.
Xilinx (XLNX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Xilinx's (XLNX) growing demand for 28-nm, 20-nm and 16-nm nodes is likely fuel Q1 Earnings. The company's product launches should further aid revenues.
Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
by Zacks Equity Research
Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.
Is Celgene (CELG) Poised For a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.
Zacks.com featured highlights: Vertex Pharmaceuticals, AGCO, Owens Corning, Five9 and Axcelis Technologies
by Zacks Equity Research
Zacks.com featured highlights: Vertex Pharmaceuticals, AGCO, Owens Corning, Five9 and Axcelis Technologies
Equifax (EFX) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Equifax's (EFX) strategic initiatives for product innovation, acquisitions and continuous share gains in North America, are likely to act as tailwinds in Q2.
What's in the Offing for F5 Networks (FFIV) in Q3 Earnings?
by Zacks Equity Research
F5 Networks Inc.'s (FFIV) GBB pricing strategy and its BIG-IQ platform will remain tailwinds in Q3.
Top Ranked Momentum Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:
Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?
by Zacks Equity Research
Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.
Vertex Pharma, A10 Networks, Microsoft, Visa and eBay highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharma, A10 Networks, Microsoft, Visa and eBay highlighted as Zacks Bull and Bear of the Day
Can Merck (MRK) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
by Zacks Equity Research
Seres Therapeutics, Inc. (MCRB) shares rose a little above 9% in the last trading session.
Bull of the Day: Vertex Pharma (VRTX)
by Brian Hamilton
Positive trial results are viewed as a game changer for the treatment of CF
Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View
by Zacks Equity Research
Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.
Company News for July 20, 2017
by Zacks Equity Research
Companies In The News are: VRTX,DISCA,UAL,CCI
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.
Here's Why Vertex Pharmaceuticals (VRTX) Soared Today
by Megan Sanks
Shares of Vertex Pharmaceuticals Incorporated (VRTX) soared 24% in morning trading on Wednesday after the company released positive results for its cystic fibrosis treatments.
Vertex (VRTX) Triple Combination CF Studies Data Positive
by Zacks Equity Research
Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs
by Arpita Dutt
Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.